Careers at Boehringer Ingelheim
Boehringer Ingelheim aims to develop and manufacture prescription and over-the-counter medications to provide customers with a better quality of life, in addition to providing animal health solutions and contract manufacturing services.
Boehringer Ingelheim operates four business segments:
- Prescription Medicines, comprising the production of prescription medication, excluding generics;
- Consumer Health Care, comprising the production of branded over-the-counter medicines, focusing on ten core brands that cover cough and cold, sore throat, general pain, gastro-intestinal disorders, leg-vein health and vitamins and minerals;
- Animal Health, comprising the development of solutions to prevent, treat and cure animal diseases; and
- Biopharmaceuticals, comprising contract development and manufacturing services for customers within the biopharmaceutical industry.
Boehringer Ingelheim traces its roots back to Albert Boehringer’s (“Boehringer”) establishment of a tartar factory in Rhine-Hessian village in 1885. The Company initially focused on the production of tartaric acid for use in food production, but switched its focus after experiments in producing citric acid formed lactic acid. Boehringer went on to refine this process of lactic acid production and began producing lactic acid on a commercial scale in 1895.
Boehringer Ingelheim launched its research and development arm, now a key facet of the Company’s business, in 1917. This ultimately enabled the Company to develop more efficient production processes and led to its production of bile acid. During the following years, Boehringer Ingelheim diversified its product portfolio, launching medications such as Lobelin, Bilaval, Codyl and Cardechol.
Boehringer Ingelheim continued this process of diversification and development during the latter half of the 20th Century, and began expanding its operations internationally. The Company also launched its animal health operations and established new research and development facilities. During the 21st Century the Company has established a number of manufacturing facilities and consolidated its production and development interests, in the process establishing itself as one of the world’s largest pharmaceutical groups.
Benefits at Boehringer Ingelheim
Business model of Boehringer Ingelheim
Boehringer Ingelheim serves customers from within the healthcare, pharmaceutical and animal health industries, as well as the general consumer market. Its end customers can be categorised broadly as follows:
- Healthcare organisations, including medical institutions and practitioners to which the Company provides a range of prescription medications;
- General consumers, for which the Company produces over-the-counter medicines for a range of minor ailments and illnesses;
- Veterinary organisations, including veterinary practices and practitioners, to which the Company provides a range of preventative and curative animal health solutions; and
- Pharmaceutical companies, to which Boehringer Ingelheim provides full-service contract manufacturing services.
Boehringer Ingelheim sells a proportion of its products to distributors, agents, affiliates and resellers, which are then authorised to market and sell the Company’s products to end customers.
Boehringer Ingelheim is a large multinational company with offices across the world. While it is based primarily in Europe, its customers are not limited by jurisdiction, with the Company serving customers across Europe, Asia, Africa, the Americas and Australasia.
Boehringer Ingelheim provides value to its customers through its established reputation as a provider of quality and reliable products, its efficient contract manufacturing services, and its commitment to research and development.
Boehringer Ingelheim is one of the largest and oldest pharmaceutical companies in the world, and has established itself as a leader in its field.
The Company devotes a significant proportion of its revenue each year to research and development, in a bid to ensure it provides the most up-to-date products to its global customer base.
Boehringer Ingelheim operates a website at www.boehringer-ingelheim.com where customers can find information on the Company’s products and services. Boehringer Ingelheim, however, does not operate an online sales channel. The Company principally makes sales through its own direct sales team, which deals with the Company’s institutional customers.
In countries where Boehringer Ingelheim has a less significant presence, notably in the Middle East and North Africa, the Company utilises a network of authorised distributors, independent sales agents, resellers and affiliates to extend its sales reach. According to its own information, the Company has 146 affiliates worldwide.
Boehringer Ingelheim reaches its general consumer customers through various pharmacy chains.
Boehringer Ingelheim does not provide any self-service offerings to its customers. The Company’s institutional customers within the healthcare and veterinary care sectors deal directly with members of the Boehringer Ingelheim sales team. The Company employs a dedicated team of representatives that interact directly with medical institutions and practitioners to market and sell the Company’s products.
Customers of Boehringer Ingelheim’s contract development and manufacturing services also deal directly with Company representatives as is necessary in accurately establishing their individual requirements. End consumers are only able to access the Company’s prescription and over-the-counter products through certified medical and pharmaceutical practitioners.
Boehringer Ingelheim makes information available to its customer through its website, including details that enable customers to contact the Company directly with feedback and enquiries. The Company also has accounts with Facebook, Twitter, YouTube, Instagram, LinkedIn and Pinterest through which it can interact directly with its customers.
Boehringer Ingelheim is a global, research-driven pharmaceutical company. The Company researches, develops, manufactures, and markets human and veterinary pharmaceutical products in its native Germany and internationally across Europe, Asia, Africa, the Americas and Australasia.
Boehringer Ingelheim develops and sells prescription medications in that aim to treat or prevent cardiovascular, diabetes, oncology, respiratory, central nervous system, and virology conditions; over-the-counter consumer healthcare products for minor illnesses; and animal health products, such as biologicals and natural care products for companion animals, horses and cattle.
It also serves customers within the pharmaceutical sector by providing end-to-end contract manufacturing services.
Boehringer Ingelheim partners with a number of companies throughout the development, manufacturing and sale of its various products. This includes:
- Research and development partnerships, primarily with companies operating within the fields of consumer health, prescription medications, biopharmaceuticals and animal health;
- Funding and joint-venture partnerships, either providing funding to research projects and start-up companies or receiving funding from private equity and venture capital firms; and
- Strategic alliances, which comprise collaborations in development and innovation with high-profile companies within the healthcare space.
Boehringer Ingelheim has launched a number of well-publicised partnerships in recent years, including a deal with Propeller Health to jointly develop solutions for people living with COPD and asthma, a tie-up with AbbVie to help companies expand their cancer treatment businesses, and a joint project with Humana dedicated to improving health care and reducing costs sufferers of chronic diseases.
Boehringer Ingelheim’s key resources are its technology and intellectual properties, its manufacturing facilities, its sales and distribution channels, and its personnel – notably those working within the Company’s research and development team.
Searches of records held by the US Patent and Trademark Office identified numerous patent applications filed in Boehringer Ingelheim’s name, including applications entitled ‘Binding molecules for BCMA and CD3’, ‘Aldosterone synthase inhibitors’ and ‘Inhibitors of cytomegalovirus’.
Boehringer Ingelheim incurs costs primarily in relation to the research and development of its products, the operation of manufacturing facilities and acquisition of supplies, the distribution and sale of its products, and the retention of its personnel.
In 2015 the Company’s research and development costs corresponded to around 20.3% of the Company’s total net sales for the year.
Boehringer Ingelheim employs more than 45,000 staff worldwide, representing cost in the form of salaries and benefits, and operates offices across multiple continents accruing costs in the form of rent and utilities.
Boehringer Ingelheim generates revenue through its four business segments. This primarily includes:
- the production and sale of prescription drugs;
- the production and sale of consumer-focused over-the-counter medications;
- the development and sale of animal health solutions; and
- the provision of contract manufacturing services.
In 2015 Boehringer Ingelheim recorded net sales of €14.8 billion, up from the €13.3 billion in net sales recorded in 2014. The vast majority of these sales came from the Company’s prescription medication business, which accounted for €10.7 billion of the Company’s total net sales for the year. Boehringer Ingelheim’s over-the-counter medication sales and animal health solutions sales both accounted for around €1.5 billion in sales, while biopharmaceutical services generated just €0.6 billion in sales.
info: Hubertus has been Member of Boehringer Ingelheim’s Board of Managing Directors since 2009 and has been its Chairman and Chief Executive Officer since 2016, having previously served as Chief Financial Officer. Baumbach also chairs the Company’s Family Council. Outside of Boehringer Ingelheim, Baumbach He serves as a member of the Advisory Board at Baden-Württembergische Bank, as a member of the Supervisory Board at KWS Saat AG, and as a member of the Advisory Board at Landesbank Baden-Wuerttemberg since.
info: Joachim has served as a member of Boehringer Ingelheim’s Board of Managing Directors since 2012. He is responsible for overseeing the Company’s Animal Health and Consumer Health Care operations. Hasenmaier first joined the Company in 2001 as Corporate Senior Vice President of Animal Health. In 2011 he was promoted to the position of Corporate Vice President of PM Mature Markets, covering the UK and Ireland, the Nordics, Benelux, Canada, and Australia.
info: Michel has served as a member of Boehringer Ingelheim’s board OF Managing Directors since 2016, having previously served as the Company’s Senior Corporate Vice President of Research and Non-Clinical Development. Pairet first joined Boehringer Ingelheim in 1992 and has served in a number of different roles, including Head of Pharmacology, Head of Pulmonary Diseases Research, Head of the German Research Site, and Head of worldwide Research. Pairet has several patents filed in his name and has published a number of scientific papers and book chapters. He holds a doctorate in Veterinary Medicine and a PhD in Physiology and Pharmacology.
info: Allan has served as a members of the Board of Managing Directors at Boehringer Ingelheim 2013. He is responsible for overseeing the Company’s pharmaceutical marketing and sales and its biopharmaceutical operations. Hillgrove previously served as the Company’s Head of Established Markets, and as a member of its Corporate Board Division for Pharmaceutical Marketing and Sales.
408.000+ job opportunitiesStart here!